NYSE:JNJ

"We Have a Health Disparities Problem in America": Meet a Woman on a Mission to Improve Healthcare for Black Women

Summary: 

The U.S. has one of the highest maternal mortality rates in the developed world, with women of color especially at risk. Dr. Robyn R. Jones, Senior Medical Director at Johnson & Johnson, is determined to change that and find ways to address this urgent crisis.

Article

The U.S. has one of the highest maternal mortality rates in the developed world, with women of color especially at risk. Dr. Robyn R. Jones, Senior Medical Director at Johnson & Johnson, is determined to change that and find ways to address this urgent crisis.

4 Latest Facts About Johnson & Johnson's Investigational COVID-19 Vaccine

Summary: 

A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.

Blog

A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.

Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine With the Imbokodo Study

The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
Blog

Since the start of the pandemic, Johnson & Johnson has been working to help address the devastating impacts of COVID-19 through the power of its science, the size of its global reach—and the know-how that comes from such experiences as standing up to challenges like HIV.

“I Was Working on a Potential COVID-19 Vaccine—Then My Wife Got Sick”: Meet a Researcher Whose Personal Experience Is Fueling His Fight Against the Pandemic

Within a matter of weeks, Ramon Polo's work and home life were completely changed by the novel coronavirus—and he's a stronger scientist and husband for it.
Blog

In late January—weeks before many people had even heard of the novel coronavirus—Ramon Polo, PharmD, Ph.D., started to work on finding solutions to fight the virus, which data suggested had the potential to become a global pandemic.

As the Vice President of Regulatory Affairs for Infectious Diseases and Vaccines and Global Public Health at Johnson & Johnson, Dr. Polo quickly began to focus on working with healthcare authorities across the globe to collaborate on the development of both therapeutic treatments and a potential vaccine for the rapidly spreading novel coronavirus.

The Road to a Vaccine, Season 2, Ep. 2: How New COVID-19 Outbreaks Are Impacting a Global Return to Normal

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

In Episode 2, Lisa Ling talks with Dr. Francis Collins, Director, NIH about the latest on treatments and vaccines. Also, Harvard's Dr. Ashish Jha shares how the virus affects the body and Johns Hopkins' Dr. Tom Inglesby explains what the new data on spread means for people.

The Road to a Vaccine, Season 2, Ep. 1: How Lessons Learned in Fighting HIV Help Us Battle COVID-19

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

In the Season 2 premiere, Lisa Ling checks into the AIDS 2020 conference to talk with HIV advocate Laverne Cox and Johnson &. Johnson Chief Scientific Officer Paul Stoffels, M.D., about how HIV vaccine research is informing work on COVID-19 vaccines.

5 Latest Facts About Johnson & Johnson's Ebola Vaccine

As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
Blog

One of the world's deadliest viral diseases was discovered in 1976 in Zaire, now known as the Democratic Republic of the Congo (DRC), near the Ebola River.

Since then, there have been 30 outbreaks of Ebola Virus Disease (EVD)—the worst of which hit in West Africa in 2014. During that two-year epidemic, more than 11,000 people died in Guinea, Liberia and Sierra Leone. Two in five individuals who were infected with the disease, then lost their lives.

"AIDS Won't Stop for COVID-19": Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History

Summary: 

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Blog

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

#BacktheFrontline: Joe Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson

Multimedia with summary

Accelerated innovation. Resources in the hands of health workers. Profit returned to the frontline.

Learn more about how we #BackTheFrontline by investing in innovators developing scalable solutions to COVID-19 from Johnson & Johnson Impact Ventures Chair Joe Wolk.

Follow along with us on @JNJGlobalHealth on Twitter and/or Instagram to hear from our leaders, employees and partners around the world about how YOU can meaningfully contribute.

Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine

Summary: 
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19
Press Release
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19

Pages

Subscribe to NYSE:JNJ